Roth CH Acquisition III Co. ROCR 深 滬
等待開盤 07-23 09:30:00 美东时间
9.16
0.000
0.00%
華盛通- 最 高--
- 今 開--
- 成交量 0股
- 最 低 --
- 昨 收 9.16
- 總市值 1.35亿
- 52周最高 10.10
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 8.505
- 委 比 0.00%
- 總股本 1478.30万
- 歷史最高 10.10
- 量 比 0
- 振 幅 0.00%
- 歷史最低 8.505
- 每 手 1
- 風險率 0.00%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Neurocrine Biosciences Appoints Lewis Choi as Chief Information Officer
SAN DIEGO, June 9, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the appointment of Lewis Choi as Chief Information Officer, effective June 9, 2025. Choi, ...
06-10 04:05
Neurocrine Biosciences Appoints Dr. Sanjay Keswani as Chief Medical Officer
Accomplished physician-scientist brings more than 20 years of industry leadership experience and broad R&D expertise in multiple therapeutic areas SAN DIEGO, April 4, 2025 /PRNewswire/ -- N...
04-04 20:00
Neurocrine Biosciences Announces CEO Succession Plan
Board of Directors appoints Kyle Gano, Ph.D., Chief Business Development and Strategy Officer, as CEO-elect, effective October 11, 2024 Kevin Gorman, Ph.D., to continue to serve on the Neuro...
2024-05-29 04:14
Neurocrine Biosciences Announces U.S. FDA Approval of INGREZZA® SPRINKLE (valbenazine) Capsules
SAN DIEGO, April 30, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the U.S. Food and Drug Administration has approved INGREZZA® SPRINKLE (valbenazine) caps...
2024-05-01 05:12
Nxera Pharma Notes Successful Development Progress of Partnered Schizophrenia Candidate NBI-1117568
NBI-1117568 is an oral, selective muscarinic M4 receptor agonist advancing thro...
2024-04-16 14:30
Neurocrine Biosciences to Participate at Investor Conferences in March
TD Cowen 44th Annual Healthcare Conference on March 5 in Boston Leerink Partners Global Biopharma Conference on March 12 in Miami Barclays 26th Annual Global Healthcare Conference on March 1...
2024-02-28 05:01
Neurocrine Biosciences Reports Second Quarter 2023 Financial Results and Raises 2023 INGREZZA Sales Guidance
INGREZZA® (valbenazine) Second Quarter Net Product Sales of $440 Million Representing 26% Year-Over-Year Growth INGREZZA® (valbenazine) 2023 Net Product Sales Guidance Raised to $1.77 - $1.8...
2023-08-01 19:00
达·戴维森以买入评级启动Roth CH收购III的覆盖范围，宣布目标价为13美元
DA Davidson analyst Brent Thielman initiates coverage on Roth CH Acquisition II...
2021-10-05 07:22
简介-QualTek提供业务更新，包括2021年第三季度指导
Oct 4 (Reuters) - Roth CH Acquisition III Co ROCR.O : * QUALTEK PROVIDES BUSINE...
2021-10-04 21:08
BRIEF-QualTek Provides Business Update, Includes Q3 2021 Guidance
Oct 4 (Reuters) - Roth CH Acquisition III Co ROCR.O : * QUALTEK PROVIDES BUSINE...
2021-10-04 21:08
